Immunome Inc.

IMNM

$2.12B

Mid Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaBOTHELL

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 5, 2026

23d

Market Overview

Stock performance and key metrics

IMNM News

Catalyst Timeline

1 upcoming, 0 past

No catalysts found.

1 more catalyst beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

How IMNM's past catalysts played out

earningsMay 2025+6%earningsNov 2024-7%earningsMay 2024-6%earningsMar 2023+9%earningsAug 2022+17%earningsMay 2022+10%earningsMar 2022+23%earningsMay 2021-9%

Drug Pipeline

AL102

Phase 3

Desmoid

Drug Name	Phase	Indication	Designations	Patent
AL102	Phase 3	Desmoid	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in Immunome Inc.'s drug pipeline?→

CatalystAlert tracks 1 drug candidate in Immunome Inc.'s (IMNM) pipeline across Phase 3. Its lead program is AL102 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Immunome Inc.'s next FDA catalyst?→

Immunome Inc.'s (IMNM) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track IMNM biotech catalysts?→

Add IMNM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immunome Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply